𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Flavonoid compounds: a review of anticancer properties and interactions with cis-diamminedichloroplatinum(II)

✍ Scribed by Beata Kosmider; Regina Osiecka


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
139 KB
Volume
63
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Interaction of poly C with cis- and tran
✍ Dennis P. Strommen; Warner L. Peticolas πŸ“‚ Article πŸ“… 1982 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 450 KB πŸ‘ 1 views

## Abstract The interactions of the ribonucleotide poly C with __cis__‐ and __trans__‐diamminedichloroplatinum (II) were probed with Raman spectroscopy. Both platinum compounds attack the __N__‐1 position of the cytosine residue, while the __trans__ form appears to attack the PO~2~^βˆ’^ as well. Rama

Interaction of topoisomerase I inhibitor
✍ Roseanne E. Bosciai; Timothy Korbut; Sylvia A. Holden; Gulshan Ara; Beverly A. T πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 French βš– 576 KB

The cytotoxicity of the topoisomerase-I inhibitors, camptothecin and topotecan, toward the SCC-25 human head-andneck squamous-carcinoma cells and the SCC-25/CDDP sub-line made resistant to cis-diamminedichloroplatinum(ll) was assessed alone and in combination with radiation. Topotecan was less cytot

Therapeutic efficacy of two-route chemot
✍ Hiroaki Kobayashi; Keitaro Hasuda; Shun'Ichiro Taniguchi; Tsuneo Baba πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 French βš– 664 KB

To enhance the therapeutic effect of conventional TRC using intra-arterial (i.a.) DDP plus simultaneous i.v. STS, we combined the AT-11-induced hypertension method with TRC and evaluated its efficacy for a rat uterine tumor, using the simulation of intra-arterial chemotherapy for human uterine tumor

Chemotherapy for advanced head and neck
✍ Edward T. Creagan; Thomas R. Fleming; John H. Edmonson; James N. Ingle; John E. πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 294 KB πŸ‘ 3 views

Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m2, day 1; cyclophosphamide, 400 mg/m2, day 3; and cis-diamminedichloroplatinum, 20 mg/m2/1 hour, days 1-3 (CAP-3). A regression rate of only 7% (0112 squamous cell carcinomas; 112 ad